BioAtla Investor Presentation Deck

UPS - ● • Written feedback received from the FDA to the proposed part 2 of the Phase 2 study design, including selection of primary endpoint (ORR) and size of the study (n=80) ● Part 2 of the Phase 2 study (potentially registrational) • FDA supportive of including a more intensive dosing arm ● • Protocol being finalized post FDA written feedback Anticipate study enrollment commencement by year-end bicatla BioAtla| Overview 14

View entire presentation